|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2014
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Keytruda
|
|
gptkbp:chemical_formula
|
C152 H201 N297 O61 S6
|
|
gptkbp:clinical_trial
|
gptkb:KEYNOTE-001
gptkb:KEYNOTE-002
gptkb:KEYNOTE-006
gptkb:KEYNOTE-024
gptkb:KEYNOTE-189
gptkb:KEYNOTE-407
gptkb:KEYNOTE-598
gptkb:KEYNOTE-716
gptkb:KEYNOTE-775
Phase II
Phase III
Phase I
KEYNOTE-789
|
|
gptkbp:contraindication
|
gptkb:Canis_lupus
active infection
hypersensitivity to pembrolizumab
|
|
gptkbp:developed_by
|
gptkb:Merck_&_Co.
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pembrolizumab
|
|
gptkbp:indication
|
advanced cancer
|
|
gptkbp:invention
|
2028
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
immune checkpoint inhibition
|
|
gptkbp:pharmacokinetics
|
half-life of approximately 26 days
increases T-cell activity
|
|
gptkbp:research_areas
|
gptkb:cancer_treatment
gptkb:immunotherapy
oncology
|
|
gptkbp:route_of_administration
|
intravenous
|
|
gptkbp:side_effect
|
fatigue
nausea
hepatitis
diarrhea
rash
pneumonitis
colitis
endocrinopathies
pruritus
|
|
gptkbp:targets
|
gptkb:PD-1
|
|
gptkbp:used_for
|
treatment of melanoma
treatment of Hodgkin lymphoma
treatment of non-small cell lung cancer
treatment of head and neck squamous cell carcinoma
|
|
gptkbp:weight
|
149 k Da
|
|
gptkbp:bfsParent
|
gptkb:KEYNOTE-890
gptkb:Cemiplimab
gptkb:KEYNOTE-001
gptkb:KEYNOTE-407
gptkb:KEYNOTE-598
|
|
gptkbp:bfsLayer
|
7
|